Can Methadone Cause Cirrhosis of the Liver?

Methadone has not been shown to cause cirrhosis on its own in human studies. The drug does stress the liver, and animal research demonstrates dose-dependent tissue damage, but the overwhelming driver of cirrhosis among people on methadone maintenance is hepatitis C infection, often compounded by alcohol use. That distinction matters because it changes how you and your doctor should think about liver monitoring and risk reduction while on methadone therapy.

How Methadone Puts the Liver to Work

Methadone is processed almost entirely in the liver. The main pathway involves an enzyme called CYP3A4, which converts methadone into an inactive breakdown product. A second enzyme, CYP2B6, also plays a major role in liver-based methadone processing.¹ The activity of these enzymes varies widely between individuals, which is why some people clear methadone quickly while others process it slowly at the same dose.² Because the liver handles so much of the work, any pre-existing liver damage can change how methadone behaves in your body, and methadone itself can place measurable stress on liver cells.

What Methadone Does to Liver Enzymes in People

The clearest human data we have comes from patients in methadone maintenance programs who were tracked over time. In one study following patients for 24 months, only about 3 to 4 percent developed elevated levels of the standard liver-damage markers ALT and AST. But half the patients had abnormal levels of a different enzyme, alkaline phosphatase (ALP). The researchers interpreted that pattern as a sign of a cholestatic type of liver stress, meaning methadone may suppress bile flow rather than directly destroying liver cells the way heavy alcohol use does.³

A separate study looked at patients who arrived at the hospital with acute methadone poisoning. In that group, about a quarter had elevated AST and roughly a fifth had elevated ALT, with ALP up in about 12 percent. The enzyme bumps were mostly mild, less than three times the upper limit of normal, and they returned to baseline during hospitalization. The researchers found no clear link between the dose of methadone consumed and how high the enzymes went.⁴ So while methadone can nudge liver enzymes upward, the effect in humans tends to be modest and often temporary.

The Animal and Lab Evidence Is More Alarming

If you only looked at animal studies, the picture would seem more dire. In rats given methadone at varying doses, liver enzymes rose sharply at every dose tested, inflammatory markers climbed, and tissue samples showed dose-dependent damage under the microscope.⁵ In cell-culture experiments, methadone was among the most toxic opioids tested on liver cell lines, causing significant damage at relatively low concentrations.⁶

Why the gap between what happens in a dish or a rat and what clinicians see in patients? Part of the answer is dosing. The concentrations used in lab studies often exceed what human liver tissue encounters at therapeutic doses. Another part is time. Rats in these experiments receive methadone over weeks, not years, and the endpoints measured are tissue inflammation and enzyme changes, not cirrhosis itself. These studies tell us methadone has the biological capacity to injure liver cells, but they do not tell us how often that injury progresses to scarring and cirrhosis in people taking standard maintenance doses.

Hepatitis C Is the Real Cirrhosis Driver in This Population

The single most important thing to understand about cirrhosis in methadone patients is that hepatitis C virus (HCV) infection is staggeringly common in this group. Studies of methadone maintenance programs report HCV antibody rates between 67 and 96 percent.⁷ Untreated chronic hepatitis C is the classic pathway to liver fibrosis and eventually cirrhosis, and it operates on a timeline of decades. Among HCV-positive methadone patients who underwent liver stiffness testing in one program, a quarter already had cirrhosis, with two of those patients in the decompensated stage where the liver is failing.⁸

A randomized trial that directly compared liver safety between methadone and buprenorphine/naloxone found no evidence of liver damage from either medication over six months. The only significant predictor of worsening liver enzymes was hepatitis B or C infection, not which opioid treatment the patient was receiving. Patients who did show extreme liver-test spikes were more likely to have picked up new hepatitis infections or to have used illicit drugs early in treatment.⁹ That finding is reassuring: the medications themselves were not the problem. The viruses were.

How Alcohol Multiplies the Risk

Alcohol use is common among people with opioid use disorder, and when methadone and alcohol overlap, the liver takes a harder hit than either substance alone would deliver. In cultured human liver cells, pre-exposing the cells to alcohol dramatically lowered the concentration of methadone needed to cause damage, reducing the half-maximal toxic concentration by 40 to 60 percent.¹⁰ Even at opioid levels that seemed safe on their own, metabolic function in the liver cells was significantly impaired after alcohol exposure.

Forensic pathology data from people with long histories of using both illicit methadone and alcohol showed marked liver changes: inflammation, expansion of scar tissue around blood vessels, and early disruption of the liver’s normal architecture, features consistent with a transition toward cirrhosis.¹¹ The combination of opioids and alcohol accelerated fibrosis in ways that neither substance did alone. If you are on methadone maintenance and you drink, your liver is facing a compounded threat that goes beyond simple addition of two risks.

The Ethnicity and Genetics Wrinkle

Your genetic makeup affects how quickly you process methadone, and there are hints it may also affect liver risk. A study looking at fibrosis progression in patients with hepatitis C found that methadone use was associated with a non-significant 41 percent increase in advanced fibrosis risk among White patients but a 51 percent reduction in risk among African American patients. White male methadone users showed a 2.1-fold increased risk of advanced liver inflammation, though that result also did not reach statistical significance.¹² These numbers are suggestive rather than definitive, but they point toward a genuine biological difference rather than a fluke.

The likely explanation involves the CYP2B6 gene. Certain variants of this gene slow methadone metabolism dramatically. Carriers of the CYP2B6*6/*6 variant clear one form of methadone about 45 percent more slowly than people with the standard gene version, meaning the drug lingers in their bloodstream and liver longer.¹³ This variant is more common in people of African descent. On the other end, carriers of CYP2B6*4 clear methadone three to four times faster. The slower your metabolism, the longer each dose sits in your liver, and the more opportunity there is for low-level cellular stress to accumulate. The variant that slows metabolism the most also diminishes the enzyme’s ability to break methadone down to about one-fifth normal efficiency.¹⁴ Whether this translates into meaningfully higher liver injury over years of maintenance therapy is still an open question, but it is biologically plausible.

Methadone in People Who Already Have Cirrhosis

A different practical question arises when someone already has cirrhosis and needs opioid maintenance. Can they still take methadone safely? The short answer is yes, with caveats. In severe liver disease, methadone’s half-life increases because the damaged liver cannot process it as quickly. Systematic reviews note that methadone should be used cautiously in patients with significant liver failure, given at lower doses, and is contraindicated in severe liver disease.¹⁵

Interestingly, when researchers actually measured blood levels of methadone in patients with varying degrees of liver fibrosis and cirrhosis, they found that liver scarring did not significantly change the dose-adjusted concentration of methadone in the blood, even in people with advanced cirrhosis.¹⁶ That seems contradictory to the recommendation for dose caution, but the researchers still advised close monitoring because individual variation is wide and the consequences of accumulation are serious. The takeaway is that a cirrhotic liver does not predictably spike methadone levels, but the margin of safety narrows, so closer supervision is warranted.

When Cirrhosis Gets Serious Enough for Transplant

For people on methadone who develop end-stage liver disease, liver transplantation is an option that should not be dismissed. Early studies of transplant outcomes in methadone-maintained patients found that survival rates were comparable to the national average for transplant recipients.¹⁷ Another study reported that patients on methadone maintenance should be evaluated using the same criteria applied to patients with alcohol-related liver disease, and that weaning off methadone before transplant was not necessary.¹⁸

That said, the transplant experience is not identical. A matched comparison found that methadone-maintained transplant recipients needed significantly more anesthesia during surgery and more pain medication afterward. More of the methadone group developed severe recurrent hepatitis C infection after transplant, and their survival was somewhat worse: 60 percent versus about 79 percent in the comparison group. Even with those complications, the researchers concluded that the data did not support withholding transplant from people on methadone maintenance.¹⁹ The poorer outcomes seemed driven more by the hepatitis C burden than by methadone itself, and the landscape has shifted since the arrival of highly effective antiviral treatments for HCV.

Does Buprenorphine Treat the Liver Any Differently?

If you are concerned about liver safety on opioid maintenance, you may wonder whether buprenorphine is a better option. The direct comparison data are reassuring on both sides. In the randomized trial mentioned earlier, changes in liver enzymes did not differ between the two medications over six months, and neither caused liver damage.⁹ An outpatient comparison similarly found no significant difference in liver-test abnormalities between the two drugs.²⁰ So choosing between them based purely on liver safety is not well supported by the evidence. Other factors, like convenience of dosing, retention in treatment, and individual response, are usually more important in that decision.

Drug Interactions That Can Affect the Liver During Treatment

Many methadone patients with hepatitis C will be treated with antiviral medications, and those drugs can interact with methadone through the same liver enzymes. Certain antiviral combinations alter methadone blood levels. However, studies that tracked patients receiving both methadone and HCV antivirals found that the interactions did not produce clinically meaningful opioid withdrawal or toxicity, meaning concurrent treatment is generally feasible.²¹ This is significant because treating hepatitis C is the single most effective thing a methadone patient can do to prevent cirrhosis. Concerns about drug interactions should not be a barrier to starting antiviral therapy.

What Monitoring Looks Like in Practice

If you are on long-term methadone, your provider should be checking liver enzymes periodically. The pattern to watch for is not a dramatic spike in ALT and AST, which would signal acute cell death, but a gradual rise in ALP, which may indicate the cholestatic stress pattern associated with methadone.³ Equally important is screening for hepatitis B and C, since undiagnosed viral hepatitis is the real threat lurking behind abnormal liver tests in this population. If you have not been tested, ask. If you tested positive years ago but never received treatment, the newer antiviral regimens are highly effective and work well alongside methadone maintenance.

For patients with known liver fibrosis or cirrhosis, measuring methadone blood levels can supplement clinical judgment, although fibrosis alone does not reliably predict how your body handles the drug.¹⁶ The genetic variability in methadone metabolism means two people with similar liver damage can process the drug at very different speeds. Pharmacogenomic testing, which identifies your CYP2B6 status, is available and could help guide dosing, though it is not yet standard practice in most clinics.²²

The Illicit Methadone Problem

Most of the research discussed so far involves pharmaceutical-grade methadone taken at prescribed doses under medical supervision. The picture changes when methadone is obtained illicitly. Illicit methadone often comes with uncontrolled dosing, unknown purity, and concurrent use of alcohol and other drugs. The forensic autopsy data showing progression toward cirrhosis came specifically from people with long histories of combined illicit methadone and alcohol use, not from clinic patients on stable doses.¹¹ The distinction is important. Supervised methadone maintenance, with its controlled dosing and medical oversight, carries far lower liver risk than unsupervised opioid use combined with alcohol. This is one more reason why enrollment in a formal treatment program matters for long-term health, not just addiction management.

1
PubMed. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone
2
PubMed. Methadone–metabolism, pharmacokinetics and interactions
3
PubMed Central. Effects of Methadone on Liver Enzymes in Patients Undergoing Methadone Maintenance Treatment
4
Journal of Toxicology. Investigating Changes in Liver Enzyme Levels in Patients With Acute Methadone Poisoning
5
PubMed Central. Histopathological study of liver tissue due to methadone consumption and its effect on liver enzymes and inflammatory indices in rat
6
Alternatives to Laboratory Animals. Hepatotoxicity of Opiates and Cocaine on Different Hepatic Cellular Systems
7
PubMed Central. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients
8
PubMed. Hepatitis C Virus Elimination in Methadone-treated Patients: Implementation of Hepatology Clinic in a Methadone Treatment Program
9
PubMed Central. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial
10
PubMed. Potentiation of heroin and methadone hepatotoxicity by ethanol: an in vitro study using cultured human hepatocytes
11
Клінічна та профілактична медицина. ГЕПАТОТОКСИЧНІ ЕФЕКТИ, ОБУМОВЛЕНІ КОМБІНОВАНИМ СПОЖИВАННЯМ ОПІОЇДНИХ НАРКОТИКІВ І АЛКОГОЛЮ
12
PubMed. Finasteride and methadone use and risk of advanced hepatitis C related liver disease
13
PubMed Central. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism
14
Drug Metabolism and Disposition. Methadone N-Demethylation by the Common CYP2B6 Allelic Variant CYP2B6.6
15
PubMed Central. Opioid Drugs in Patients With Liver Disease: A Systematic Review
16
PubMed. Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations
17
PubMed. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation
18
Liver Transplantation. Liver transplantation for patients on methadone maintenance
19
Liver Transplantation. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients
20
Addictive Disorders & Their Treatment. Comparative Safety and Side Effect Profiles of Buprenorphine and Methadone in the Outpatient Treatment of Opioid Dependence
21
PubMed. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
22
PubMed Central. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics